Patent ID: 11919858
Assignee: CALGENT BIOTECHNOLOGY CO., LTD.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A method for therapeutically treating multiple myeloma, colorectal adenocarcinoma, breast cancer or ovarian cancer, comprising administrating an effective amount of the compound of Formula (I) to a cell or a subject, wherein
R1 is a halogen;
each R2 is the same or different, representing H, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, NH2, NO2, C1-10alkyloxy, C1-10alkylthio, C1-10alkylamino, C1-10alkyloxyC1-10alkyl, OH or CN, C6-10aryl or C5-7heterocyclic having 1 to 3 heteroatoms selected from the group consisting of N, O and S;
R3 is H, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, NH2, NO2, OH or CN;
R4 is H, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, NH2, NO2, OH or CN;
R5 is OH, C3-8cycloalkyl, phenyl unsubstituted or substituted with one to three same or different substituents selected from OH, CN, halogen, NH2 or C1-4alkylpiperazinyl, C1-6alkylpiperazinyl, C1-6alkylpyridinyl, C1-6alkylpyrrolidinyl, pyridinyl, pyrimidinyl, pyrazinyl. piperazinyl, pyrrolidinyl, thiazolyl, benzimidazolyl, pyrazolyl, indazolyl, quinolinyl, indolyl, azaindolyl, azaindazolyl, deazapurinyl, indanyl, morpholinoyl or C1-4alkylmorpholinoyl, each of which is unsubstituted or substituted with one, two or three groups selected from OH, CN, halogen, NO2, C1-4alkyl, or NH2;
X is —C(O)
Y is —N—;
m is an integer of 0-3; and
n is an integer of 1-7;
or a tautomer, enantiomer, stereoisomer thereof, or a solvate or a pharmaceutically acceptable salt thereof.